Latest papers

DNA microarray gene expression profile of marginal zone versus follicular B cells and idiotype positive marginal zone B cells before and after immunization with Streptococcus pneumoniae.

A common idiotype in IgE and its relation to recognition of the grass pollen allergen Phl p 2.

Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.

Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.

Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells.

Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo.

[Preparation of heat shock protein 70 (Hsp70) and idiotypic determinant single-chain antibody (Id-ScFv) in a patient with B-cell chronic lymphatic leukemia (B-CLL) and antitumor effect of peptide complex Hsp70-Id]

The immunoglobulin constant region contributes to affinity and specificity.

An immunoglobulin E-reactive chimeric human immunoglobulin G1 anti-idiotype inhibits basophil degranulation through cross-linking of FcepsilonRI with FcgammaRIIb.

Evidence in favor of a role of idiotypic network in autoimmune hemolytic anemia induction: theoretical and experimental studies.

Gender dichotomy in antibody response in a T-cell lymphoma: involvement of IL-13 and gonadal hormones.

HLA class II-like antiidiotypic antibodies from highly sensitized patients inhibit T-cell alloresponses.

Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin.

[From the allergen-recognition by antibodies to new therapeutic concepts].

How affinity influences tolerance in an idiotypic network.

Immune therapies.

Generation of Her-2/neu vaccine utilizing idiotypic network cascade.

Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients.

Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.

T cells from multiple sclerosis patients recognize multiple epitopes on Self-IgG.